Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13

About this update from Artelo Biosciences, Inc.

[{"type":"image","alt":"Artelo Biosciences","displaySize":"","headline":null,"caption":"Artelo Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":183,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dtRWcM_YXYcz7bexobLzxA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0fcfe43e16f7cfc8e2a0ef70f1c6364e","width":183,"height":80}},"lazy":false},{"type":"text","content":"Extends Patent Protection Through December 2041","length":47,"tagName":"p"},{"type":"text","content":"ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia","length":102,"tagName":"p"},{"type":"text","content":"SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the European Patent Office (EPO) has issued a Notice of Allowance for Artelo’s European patent application No. 21827629.3. The application covers the intended commercial formulation of ART27.13, the Company’s peripherally selective cannabinoid agonist currently under evaluation in the Phase 2 CAReS trial for the treatment of cancer-related anorexia.","length":672,"tagName":"p"},{"type":"text","content":"The allowed claims protect compositions of ART27.13 dispersed in polyethylene glycol, including the Company’s intended commercial formulation. This development marks a major milestone in Artelo’s global intellectual property strategy and positions the Company for long-term value creation.","length":289,"tagName":"p"},{"type":"text","content":"“Securing this Notice of Allowance from the EPO is an important step in protecting the commercial potential of ART27.13,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Cancer-related anorexia affects over 60% of people with advanced stage cancer, yet there are currently no approved therapies to treat it in the US, UK, or EU. With a patent term expected through December 2041, we believe this achievement significantly enhances the value of ART27.13 as we aim to bring f...

More updates from Artelo Biosciences, Inc.